TY - JOUR
T1 - Susceptibility of colistin-resistant pathogens to predatory bacteria
AU - Dharani, Sonal
AU - Kim, Dong Hyun
AU - Shanks, Robert M.Q.
AU - Doi, Yohei
AU - Kadouri, Daniel E.
N1 - Funding Information:
Research was sponsored by the National Institutes of Health grant R01AI104895 to Y. Doi and the U.S. Army Research Office and the Defense Advanced Research Projects Agency grant to D. E. Kadouri and R. M. Q. Shanks, under Cooperative Agreement Number W911NF-15-2-0036 . The views and conclusions contained in this document are those of the authors and should not be interpreted as representing the official policies, either expressed or implied, of the Army Research Office, DARPA, or the U.S. Government. The U.S. Government is authorized to reproduce and distribute reprints for Government purposes notwithstanding any copyright notation hereon.
Funding Information:
Research was sponsored by the National Institutes of Health grant R01AI104895 to Y. Doi and the U.S. Army Research Office and the Defense Advanced Research Projects Agency grant to D. E. Kadouri and R. M. Q. Shanks, under Cooperative Agreement Number W911NF-15-2-0036. The views and conclusions contained in this document are those of the authors and should not be interpreted as representing the official policies, either expressed or implied, of the Army Research Office, DARPA, or the U.S. Government. The U.S. Government is authorized to reproduce and distribute reprints for Government purposes notwithstanding any copyright notation hereon.
Publisher Copyright:
© 2017 Institut Pasteur
PY - 2018/1
Y1 - 2018/1
N2 - The increase in multidrug-resistant Gram-negative bacterial infections has forced the reintroduction of antibiotics such as colistin. However, the spread of the plasmid-borne mcr-1 colistin resistance gene have moved us closer to an era of untreatable Gram-negative infections. To evaluate whether predatory bacteria could be used as a potential therapeutic to treat this upcoming threat, the ability of Bdellovibrio bacteriovorus and Micavibrio aeruginosavorus to prey on several clinically relevant mcr-1-positive, colistin-resistant isolates was evaluated. No change in the ability of the predators to prey on free swimming and biofilms of prey cells harboring mcr-1 was measured, as compared to their mcr-1 negative strain.
AB - The increase in multidrug-resistant Gram-negative bacterial infections has forced the reintroduction of antibiotics such as colistin. However, the spread of the plasmid-borne mcr-1 colistin resistance gene have moved us closer to an era of untreatable Gram-negative infections. To evaluate whether predatory bacteria could be used as a potential therapeutic to treat this upcoming threat, the ability of Bdellovibrio bacteriovorus and Micavibrio aeruginosavorus to prey on several clinically relevant mcr-1-positive, colistin-resistant isolates was evaluated. No change in the ability of the predators to prey on free swimming and biofilms of prey cells harboring mcr-1 was measured, as compared to their mcr-1 negative strain.
UR - http://www.scopus.com/inward/record.url?scp=85029909673&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85029909673&partnerID=8YFLogxK
U2 - 10.1016/j.resmic.2017.09.001
DO - 10.1016/j.resmic.2017.09.001
M3 - Article
C2 - 28919044
AN - SCOPUS:85029909673
VL - 169
SP - 52
EP - 55
JO - Research in Microbiology
JF - Research in Microbiology
SN - 0923-2508
IS - 1
ER -